<?xml version="1.0" encoding="UTF-8"?>
<p id="Par117">Descriptive statistics will be used to characterize the patient demographics on the study, distribution of lesions treated and dosimetric parameters of the treatments and toxicity experienced at 6â€‰weeks. Progression free survival will be tracked and reported using Kaplan Meier statistics. Changes in QOL will be reported as the minimal clinically important change comparing pre and post treatment scores by patient.</p>
